The following are the recipients from the Accelerating Commercial Development Fund:
Innate Immunotherapeutics Limited, Auckland, New Zealand (Project Director – Simon Wilkinson) will receive $550,000 over 15 months to conduct a Phase IIa clinical trial in patients with progressive forms of MS using MIS416, a naturally occurring agent derived from bacteria.
Cognosci Inc., Research Triangle Park, NC (Project Director – Feng Qiao Li, PhD) will receive $330,000 over 12 months for the efficacy testing of COG112, a molecule that mimics actions of the cholesterol transporting protein, ApoE. In the funded studies, the company will evaluate the ability of COG112 to promote myelin repair in the central nervous system (CNS) in laboratory models of MS.
The following organizations will receive financing from the Accelerating Innovation Fund:
CenTRion Therapeutics Limited, a spin out of the University of Greenwich, UK, (Project Director – Michael Leach, PhD) will receive $275,000 over 12 months for studies with compounds, related to lamotrigine, an approved epilepsy therapy, which some studies suggest also can protect nerve cells from damage. CenTrion will conduct research to determine the safety and efficacy of its original neuroprotective compounds in laboratory models of MS.
Oregon Health & Science University, Portland, OR, (Project Director – Lawrence Sherman, PhD) will receive $275,000 for the screening and efficacy of small molecule inhibitors of hyaluronidase, an enzyme that dissolves hyaluronic acid – a complex sugar molecule that accumulates in MS lesions. Dr. Sherman’s group has found that by-products resulting from breakdown of hyalunoric acid prevent myelin repair. This project will assess whether myelin repair blockage can be overcome by inhibiting the activity of hyaluronidase.